Study of Environmental Risk Factors in Myositis Patients With and Without Anti-Synthetase Syndrome Compared to Healthy Volunteers
Led by National Institute of Environmental Health Sciences (NIEHS) · Updated on 2026-10-16
580
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying autoimmune diseases, focusing on myositis, a condition that weakens muscles and may cause other health issues. This study aims to understand if people with the anti-synthetase syndrome, a form of myositis with specific autoantibodies and lung disease, have different environmental exposures before disease onset compared to other myositis patients and healthy volunteers. The goal is to identify infectious and noninfectious factors linked to this syndrome.
Participants include recent-onset myositis patients with and without the anti-synthetase syndrome and healthy volunteers. All participants undergo medical history review, physical exams, and provide blood, urine, and house dust samples. They complete questionnaires about their exposures at work, home, and elsewhere. Myositis patients also report on infections, physical exertion, sun exposure, tobacco and alcohol use, and stressful events before diagnosis. Some participants may have lung function tests and imaging as clinically needed.
Participants will collect house dust using a vacuum filter kit for future analysis. Researchers will assess medical histories, environmental exposures, and clinical data, including chest X-rays, CT scans, pulmonary tests, and biopsies when indicated. Blood and tissue samples will be stored for ongoing and future investigations. The study includes people aged 2 to 100 years, with healthy volunteers matched by age, gender, and race. Participation involves completing questionnaires, sample collection, and possible clinical tests, with the main measure being the comparison of environmental exposures before disease onset.
CONDITIONS
Brief Title
Environmental Risk Factors for the Anti-synthetase Syndrome
Research Team
A
Adam I Schiffenbauer, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Environmental Health Sciences (NIEHS)
Lead Sponsor
Who Can Participate
Age: 2Years - 100Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Diagnosis of myositis (possible, probable or definite polymyositis or dermatomyositis) within 24 months of enrollment
Chest X-ray to assess lung disease if clinically indicated
Age 2 years or older
Ability and willingness to give informed consent, complete questionnaires, and donate blood samples
For children 2 to under 18 years, parent or guardian consent and child assent as appropriate
Healthy volunteers matched by age, gender, and race without autoimmune disease or lung disease
Living in the US or Canada
You will not qualify if you...
Cancer-associated myositis diagnosed within 2 years of myositis diagnosis
Inclusion body myositis diagnosis
Myositis caused by drug, toxin, or other exposure that resolved after stopping the agent
Children under 2 years old
Medical conditions preventing safe blood draws or clinical evaluations
Cognitive impairment
Unable or unwilling to give informed consent or assent
Not living in the US or Canada at reference date
Current incarceration
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Data Collection and Sample Submission
Duration - Varies by participant
Participants complete questionnaires about their medical history and environmental exposures. They provide blood, urine, and house dust samples using a vacuum filter kit for dust collection at home.
1 or more visits depending on clinical needs
Clinical Testing as Needed
Duration - Varies by participant
Myositis patients may undergo lung function tests, imaging studies, chest X-rays, biopsies, or other evaluations as clinically indicated.
Additional visits as needed
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Long-Term Follow-Up Study for Adults Previously Treated with KYV-101 CAR T-Cell Therapy
Phase 1 Study Evaluating Safety and Preliminary Effects of CTX112, a CRISPR-Cas9 Engineered CD19-Targeting T Cell Therapy, in Adults with Refractory Autoimmune Diseases
Phase 12 Study Evaluating Intravenous CRT-402 CAR-T Cell Therapy for Refractory Autoimmune Diseases
Evaluating the Effects of PF-06823859 Versus Placebo in Adults with Active Dermatomyositis or Polymyositis Through Intravenous Infusions
Long-Term Safety and Effects of Dazukibart in Adults with Idiopathic Inflammatory Myopathies Including Dermatomyositis and Polymyositis
Evaluation of Adult and Childhood-Onset Idiopathic Inflammatory Myopathies Including Polymyositis and Dermatomyositis
Phase 2a Study of AlloNK Cord Blood-derived NK Cell Therapy Combined With Rituximab
for Relapsing B-cell Rheumatologic Diseases Including RA, Sjgrens, Myopathies, and Systemic Sclerosis
Study of Anti-CD19 CAR T-Cell Therapy for Adults with Severe Refractory Systemic Autoimmune Diseases Including Lupus, Scleroderma, DermatomyositisPolymyositis, and ANCA-Associated Vasculitis
Phase III Trial of Baricitinib Added to Usual Care for Adults With Relapsing or New Dermatomyositis
Study of Single-Dose anti-CD19 CAR T Cell Therapy for Adults With Systemic B Cell Mediated Autoimmune Diseases Including Lupus, Scleroderma, and Myositis
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Matthew A Sherman, Qingyuan Yang, Laura Gutierrez-Alamillo...